Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06219915 · ClinicalTrials.gov registry record · Phase 1
Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Placebo-Controlled Arm
A Phase 1 study, sponsored by University of Michigan.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT06219915 is a Phase 1 study that has completed, run by University of Michigan. The registered enrollment target is 13 participants.
The verdict
NCT06219915, a Phase 1 study, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
Walking with age becomes both slower and less 'automated', requiring more attention and brain resources. As a result, older adults have a greater risk of negative outcomes and falls. There is an urgent need to identify factors that can help compensate for these harmful factors and reduce walking impairments, as there are currently no effective treatments available. Investigators have recently discovered that \~20% of older adults maintain fast walking speed even in the presence of small blood vessel brain changes and leg problems, thus appearing to be protected against these harmful factors. The investigators work suggests that the brain dopamine (DA) system may be a source of this protective capacity. Investigators have also shown that lower levels of dopamine are associated with slow walking. Investigators will be investigating the role of dopamine on slow walking and other parkinsonian signs in this double-blinded, placebo-controlled study using detailed clinical assessment, assessment of dopamine activity, and clinical interventions.
Interventions
- DRUG Placebo 1
- DRUG Placebo 2
- DRUG Carbidopa 25 mg
- DRUG Carbidopa-Levodopa 25/100 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2024-03-15 |
| Est. Completion | 2024-05-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06219915
The ClinicalTrials.gov registry entry for NCT06219915 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo 1 is the first listed.
NCT06219915 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06219915 about?
NCT06219915 is a clinical study titled "Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Placebo-Controlled Arm". Walking with age becomes both slower and less 'automated', requiring more attention and brain resources. As a result, older adults have a greater risk of negative outcomes and falls. There is an urgent need to identify factors that can help compensate for these harmful factors and reduce walking imp...
What is the current status of trial NCT06219915?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2024-03-15. Estimated completion is 2024-05-30.
What interventions are being tested in trial NCT06219915?
The interventions under investigation include: Placebo 1 (DRUG), Placebo 2 (DRUG), Carbidopa 25 mg (DRUG), Carbidopa-Levodopa 25/100 mg (DRUG).
Who is sponsoring clinical trial NCT06219915?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.